Drug Profile
Research programme: neurodegenerative disorder therapeutics - Denali Therapeutics
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Denali Therapeutics Inc
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 28 Feb 2020 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA
- 28 Feb 2020 No recent reports of development identified for research development in Parkinson's-disease in USA